Eprodisate
Alternative Names: Eprodisate disodium; Eprodisate sodium; Fibrillex; Kiacta; NC-503Latest Information Update: 03 Jul 2023
Price :
$50 *
At a glance
- Originator BELLUS Health
- Developer Auven Therapeutics; BELLUS Health
- Class Alkanes; Anti-inflammatories; Small molecules; Sulfonic acids
- Mechanism of Action Serum amyloid A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Submission Withdrawal Amyloid A amyloidosis
- No development reported Sarcoidosis
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2023 BELLUS Health has been acquired by GSK
- 28 Jun 2018 No recent reports of development identified for preclinical development in Sarcoidosis in USA (PO)
- 21 Dec 2016 Discontinued - Phase-III for Amyloid A amyloidosis in USA, European Union, Russia, Israel, Peru, Mexico, India, Argentina, Turkey, Brazil, Chile, Egypt, Tunisia, Ukraine, Georgia, Japan (PO)